VASO — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-14

• ●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations and no longer included in segm…

• ●Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively, primarily focuses on the design, manufacture, sale and service of…

• The Company has ended its operations in the IT segment after the sale of VHC-IT in November 2025 and the sale of NetWolves in July 2026.

• Unless otherwise noted, this Management’s Discussion and Analysis of Financial Condition and Results of Operations relates solely to our continuing operations and does not include the operations of NetWolves. See Note C – Discontinued Operations of the notes to condensed consolidated financial state…

• Results of Operations – For the Three Months Ended June 30, 2026 and 2025

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• ●IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. We divested our former healthcare IT service business in November 2025;

• ●Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp.…

• Results of Operations – For the Three Months Ended March 31, 2026 and 2025

• Total revenue for the three months ended March 31, 2026 and 2025 was $19,356,000 and $19,462,000, respectively, representing a decrease of $106,000, or less than 1% year-over-year. On a segment basis, revenue in the professional sales service and equipment segments increased $530,000 and $118,000, r…

• Revenue in the IT segment for the three months ended March 31, 2026 was $9,561,000 compared to $10,315,000 for the three months ended March 31, 2025, a decrease of $754,000, or 7%, of which $987,000 resulted from the divestiture of the VasoHealthcare IT business in the 4th quarter of 2025, partially…

Text added vs the prior filing · source: 10-Q · 2026-08-14

• 3(ii) Bylaws (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).

• 10.1 Transaction Award Agreement between Vaso Corporation and Peter Castle

• 10.2 Amendment to Transaction Award Agreement between Vaso Corporation and Peter Castle

• 31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

• 31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• 3(ii) Amended and Re-stated Bylaws (Incorporated by reference to Report on Form 8-K filed February 12, 2026).

• 31.1 Certification of the Chief Executive Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

• 31.2 Certification of the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.